Lilly raised sales guidance for third time this year as Zepbound sales soar. Its stock is rallying.

The drugmaker continues to dominate the market for prescription weight-loss drugs in the U.S.

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketwatch.com)